Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 10/23 10:00:00 pm
122.37 USD   +0.86%
10:10a CELGENE : Provides Update on GED-0301 Inflammatory Bowel Disease Pro..
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVE : Celg, pypl
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about CELGENE CORPORATION
10:10a CELGENE : Provides Update on GED-0301 Inflammatory Bowel Disease Program
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVERS : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
10/19 CELGENE CORPORATION (NASDAQ : CELG) Files An 8-K Costs Associated with Exit or D..
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19 CELGENE : Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Pro..
10/19 CELGENE : Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Mult..
10/19 CELGENE : Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Mult..
10/18 CELGENE CORPORATION : - Results from Phase 2 Studies of Oral Ozanimod in Crohn's..
10/16 CELGENE : Results from Phase 2 Studies of Oral Ozanimod in Crohn's Disease and U..
10/16 CELGENE : Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease..
10/13 CELGENE : Sutro Marks Two Drug Development Milestones
10/12 EVOTEC : achieves first milestone in neurodegeneration alliance with Celgene
10/04 CELGENE CORPORATION : to Announce Third Quarter 2017 Results
More most relevant news
All news about CELGENE CORPORATION
10:17a CELGENE : to stop clinical trials of Crohn`s disease drug GED-0301
10:14a CELGENE : cans phase 3 trial of $710M Crohns drug GED-0301
10:10a CELGENE : Provides Update on GED-0301 Inflammatory Bowel Disease Program
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVERS : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
10/19 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/19 CELGENE : Patent Issued for Romidepsin Formulations and Uses (USPTO 9782451)
10/19 CELGENE CORPORATION (NASDAQ : CELG) Files An 8-K Costs Associated with Exit or D..
10/19 CELGENE CORP /DE/ : Costs Associated with Exit or Disposal Activities (form 8-K)
More news
Sector news : Pharmaceuticals - NEC
07:50aDJNOVARTIS : 3Q Net Profit Rises as New Drugs Offset Generic Competition
10/23 European stocks hold firm as banks, Spanish shares fall
10/23 Smith & Nephew to buy Rotation Medical for up to $210 million
10/23DJEuropean Corporate Roundup for Monday
10/23DJDrug Makers Find 'Branded Generics' Are a Source for Growth
10/23 ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/23 Mongersen Fails
10/23 CELGENE : Still A Great Pipeline, Despite A Setback
10/23 Ozanimod Even More Important For Celgene Now, But Can It Deliver In MS?
10/23 Catalysts loom for Celgene - Morgan Stanley
10/23 BIOTECH FORUM DAILY DIGEST : Behind UniQure's Massive Rally
10/23 YOUR DAILY PHARMA SCOOP : Adamis Upside Potential, J&J's SIMPONI Label Expansion..
Latest Tweets
11:02a10 Technical Levels Discussed On Monday's PreMarket Prep  
10/23Celgene Corporation initiated by Guggenheim at buy.  
10/23Top Celgene cancer drugs now 20% more expensive after latest price hikes: The.. 
10/23LOL, just now on CNBC: "Final Trade?" "Microsoft" "Cisco Systems" "Nvidia" ..
13
10/23$IBB sitting on the 50 Day MA with $AMGN, $GILD and $CELG reporting earnings ..
16
More tweets
Qtime:348
Financials ($)
Sales 2017 13 226 M
EBIT 2017 7 429 M
Net income 2017 4 475 M
Debt 2017 3 949 M
Yield 2017 -
P/E ratio 2017 22,00
P/E ratio 2018 16,80
EV / Sales 2017 7,54x
EV / Sales 2018 6,14x
Capitalization 95 736 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 148 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION5.72%95 736
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223